5-Chloro-2-methoxy-3-nitroacetophenone, = 99% (GC), 1g

tert-Butyl 4-oxotetrahydrofuran-3-carboxylate, 95.0%, 100mg

1-(4-Fluorophenyl)-2-propanol, 97.0%, 1g

GC capillary column ROTI®Cap-1, 60 m, 0.32 mm, 3.00 µm, 1 Piece(s)

(6-Bromo-4-methyl-pyridin-3-yl)-methanol, 97%, 100mg

(S)-2-Amino-2-(3,5-dimethoxyphenyl)ethanol, 97%, 100mg

tert-Butyl 4-(4-cyanobenzoyl)piperazine-1-carboxylate, 95%, 250mg

4-Chloro-2-iodopyrrolo[2,1-f][1,2,4]triazine, 98+%, 250mg

Trimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)silane, 98%, 1g

5-Ethyl-2-hydroxy-3-nitro-benzaldehyde, 1g

2-Chloro-N-(3,5-dimethyl-phenyl)-acetamide, 95.0%, 5g

O-(2-Fluorobenzyl)hydroxylamine hydrochloride, 98.0%, 5g

Plan PLPH 10x/0.25 phase contrast objective